Indeed, after screening the ability of a series of synthetic peptides corresponding to the junction sequences of p210 protein to bind according to putative anchor motifs class I and class II molecules (i.e., HLA A1, A2.1, A3.2, B8 and DR11), we and others identified some b3a2 and b2a2 breakpoint peptides able to elicit in vitro a specific T cell response both in normal donors and in CML patients [9,10]. Here, EVPL is linked to chronic myelogenous leukemia, BCR-ABL1 positive.